Q4 2024 Earnings Call Transcript March 25, 2025 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0 ...
XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...
The trial is now only enrolling participants with moderate and severe neutropenia (ANC below 1,000 cells per microliter), an ANC level consistent with the company’s targeted patient population ...
The trial is now only enrolling participants with moderate and severe neutropenia (ANC below 1,000 cells per microliter), an ANC level consistent with the company’s targeted patient population ...
The ANC testing is part of labeling, as the drug poses a risk for neutropenia. The REMS required that physicians and pharmacists be certified to prescribe and dispense the drug, which was ...
Two, that mavorixafor treatment durably and meaningfully increased participants' mean absolute neutrophil counts, or ANC, across all study populations. And three, that physicians were willing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback